[go: up one dir, main page]

MA39907A - Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) - Google Patents

Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)

Info

Publication number
MA39907A
MA39907A MA039907A MA39907A MA39907A MA 39907 A MA39907 A MA 39907A MA 039907 A MA039907 A MA 039907A MA 39907 A MA39907 A MA 39907A MA 39907 A MA39907 A MA 39907A
Authority
MA
Morocco
Prior art keywords
present
tumor
relates
aml
blood
Prior art date
Application number
MA039907A
Other languages
English (en)
Other versions
MA39907B1 (fr
Inventor
Claudia Berlin
Daniel Kowalewski
Hans-Georg Rammensee
Stefan Stevanovic
Juliane Stickel
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA39907A publication Critical patent/MA39907A/fr
Publication of MA39907B1 publication Critical patent/MA39907B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04004—Plus-end-directed kinesin ATPase (3.6.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y599/00—Other isomerases (5.99)
    • C12Y599/01—Other isomerases (5.99.1)
    • C12Y599/01002—DNA topoisomerase (5.99.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La présente invention concerne des peptides, des acides nucléiques et des cellules pour leur utilisation dans des méthodes immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie du cancer. La présente invention concerne en outre des épitopes peptidiques des lymphocytes t cytotoxiques (ltc) associés à une tumeur, seuls ou en combinaison avec d'autres peptides associés à une tumeur qui servent d'ingrédients pharmaceutiques actifs de compositions vaccinales qui stimulent des réponses immunitaires anti-tumorales. La présente invention concerne plusieurs nouvelles séquences peptidiques et leurs variants dérivés de molécules hla de classe i et des molécules hla de classe ii de cellules tumorales humaines qui peuvent être utilisées dans des compositions vaccinales pour induire des réponses immunitaires antitumorales.
MA39907A 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) MA39907B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990980P 2014-05-09 2014-05-09
GBGB1408255.6A GB201408255D0 (en) 2014-05-09 2014-05-09 Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP15732544.0A EP3140319B1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
PCT/EP2015/060168 WO2015169945A2 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)

Publications (2)

Publication Number Publication Date
MA39907A true MA39907A (fr) 2017-03-15
MA39907B1 MA39907B1 (fr) 2019-09-30

Family

ID=51032516

Family Applications (3)

Application Number Title Priority Date Filing Date
MA39907A MA39907B1 (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
MA049280A MA49280A (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
MA049287A MA49287A (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA049280A MA49280A (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
MA049287A MA49287A (fr) 2014-05-09 2015-05-08 Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)

Country Status (25)

Country Link
US (2) US10064924B2 (fr)
EP (3) EP3140319B1 (fr)
JP (1) JP6659582B2 (fr)
KR (1) KR20170003976A (fr)
CN (1) CN106459167A (fr)
AU (2) AU2015257652B2 (fr)
BR (1) BR112016025035A2 (fr)
CA (1) CA2946349A1 (fr)
CR (1) CR20160531A (fr)
DK (1) DK3140319T3 (fr)
EA (2) EA202090751A3 (fr)
ES (1) ES2747734T3 (fr)
GB (1) GB201408255D0 (fr)
HU (1) HUE045177T2 (fr)
LT (1) LT3140319T (fr)
MA (3) MA39907B1 (fr)
ME (1) ME03565B (fr)
MX (1) MX2016014711A (fr)
PL (1) PL3140319T3 (fr)
PT (1) PT3140319T (fr)
RS (1) RS59471B1 (fr)
SG (1) SG11201608332SA (fr)
SI (1) SI3140319T1 (fr)
TW (2) TWI668230B (fr)
WO (1) WO2015169945A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10000533B2 (en) 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017174645A1 (fr) * 2016-04-06 2017-10-12 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
PE20181896A1 (es) 2016-04-06 2018-12-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide agua (lma) y otros tipos de cancer
AU2017248353A1 (en) * 2016-04-07 2018-10-25 Case Western Reserve University TDP-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3034124A1 (fr) * 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Peptides de fusion avec des antigenes lies a des fragments courts de chaine invariante (cd74)
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
WO2018189661A2 (fr) * 2017-04-10 2018-10-18 Palti Yoram Prof Méthodes et composés pour le traitement du diabète
CN111533799A (zh) 2017-04-10 2020-08-14 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
EP4576103A3 (fr) 2017-10-10 2025-08-27 Gritstone bio, Inc. Identification de néoantigènes à l'aide de points chauds
CA3083242A1 (fr) * 2017-11-21 2019-05-31 Naofumi MIWA Agent inhibiteur de metastases de cellules cancereuses humaines et agent de determination de cellules cancereuses humaines
EP3714275A4 (fr) 2017-11-22 2021-10-27 Gritstone bio, Inc. Réduction de la présentation d'épitope de jonction pour des néo-antigènes
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
CN108707666B (zh) * 2018-05-28 2021-04-09 陕西中医药大学第二附属医院 Dgkz基因作为白血病检测的生物标志物的应用
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
AU2020232971A1 (en) * 2019-03-01 2021-09-23 Scott R. BURKHOLZ Design, manufacture, and use of personalized cancer vaccines
CN112409449B (zh) * 2019-08-19 2023-12-15 辽宁中健医药科技有限公司 Hla-a0201限定性kif15特异性抗肿瘤ctl优势表位肽及应用
JP2023521219A (ja) * 2020-04-14 2023-05-23 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
CN112980955A (zh) * 2021-03-05 2021-06-18 南昌大学第二附属医院 Emilin2作为胶质瘤替莫唑胺耐药检测、治疗及预后分子靶点的应用
CN113130001B (zh) * 2021-03-31 2023-07-18 甘肃中医药大学 一种天然化合物与抗肿瘤化合物配伍的筛选方法
US20240197919A1 (en) * 2021-05-04 2024-06-20 California Institute Of Technology Recombinant aavs for delivery to central nervous system and brain vasculature
WO2023025851A1 (fr) * 2021-08-24 2023-03-02 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
CN114703274B (zh) * 2022-04-01 2023-08-15 中国人民解放军总医院 Phpt1在预警和/或治疗高原病中的应用
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2025011658A1 (fr) * 2023-07-12 2025-01-16 Anda Biology Medicine Development (Shenzhen) Co., Ltd Nouveaux marqueurs pour vaccins à néo-antigènes tumoraux

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (fr) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (fr) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7033400A (en) * 1999-08-30 2001-03-26 Jehad Mikhaiel Charo Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65
EP1092779B1 (fr) * 1999-10-11 2009-11-25 Institut Pasteur Vecteurs lentiviraux pour la préparation des compositions immunothérapeutiques
EP1239866A4 (fr) * 1999-12-10 2005-02-09 Epimmune Inc Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
EP1268774A2 (fr) * 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification de genes esentiels dans des procaryotes
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
WO2003057823A2 (fr) * 2001-11-07 2003-07-17 Mannkind Corporation Synchronisation d'epitope dans les cellules qui presentent des antigenes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (fr) 2002-02-20 2003-08-28 Dyax Corp. Ligands de liaison au complexe mhc-peptide
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100692416B1 (ko) * 2003-05-26 2007-03-09 학교법인 배재학당 Ｆａｆ1 단편 및 그를 함유하는 종양 전이 억제제
JP2007534744A (ja) 2004-04-29 2007-11-29 エスケー コープ Ｆａｓ関連因子１（ｆａｓａｓｓｏｃｉａｔｅｄｆａｃｔｏｒ１）
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
PL1760088T3 (pl) 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
CN105566450A (zh) * 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 免疫疗法的新型免疫抗原表位
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
KR101224466B1 (ko) * 2010-05-20 2013-01-22 가톨릭대학교 산학협력단 토포아이소머라아제 2 알파 유래의 종양항원 단백질, 유전자, 또는 펩타이드
WO2012056407A1 (fr) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Anticorps qui se lient à des ligands de récepteurs de lymphocytes t solubles
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)

Also Published As

Publication number Publication date
EA202090751A2 (ru) 2020-07-31
EP3140319A2 (fr) 2017-03-15
EP3604327A1 (fr) 2020-02-05
TW201920246A (zh) 2019-06-01
MA49280A (fr) 2019-03-06
US20150320848A1 (en) 2015-11-12
MX2016014711A (es) 2017-10-23
AU2015257652A1 (en) 2016-09-29
HUE045177T2 (hu) 2019-12-30
ME03565B (fr) 2020-07-20
PT3140319T (pt) 2019-10-15
US10064924B2 (en) 2018-09-04
MA39907B1 (fr) 2019-09-30
TWI668230B (zh) 2019-08-11
EP3449937A1 (fr) 2019-03-06
EA202090751A3 (ru) 2020-10-30
CR20160531A (es) 2017-04-27
TW201625676A (zh) 2016-07-16
WO2015169945A2 (fr) 2015-11-12
WO2015169945A3 (fr) 2016-02-04
KR20170003976A (ko) 2017-01-10
AU2020200066A1 (en) 2020-01-30
ES2747734T3 (es) 2020-03-11
RS59471B1 (sr) 2019-12-31
BR112016025035A2 (pt) 2017-10-24
SI3140319T1 (sl) 2019-11-29
JP6659582B2 (ja) 2020-03-04
PL3140319T3 (pl) 2020-02-28
US20180311330A1 (en) 2018-11-01
DK3140319T3 (en) 2019-09-23
SG11201608332SA (en) 2016-11-29
CN106459167A (zh) 2017-02-22
CA2946349A1 (fr) 2015-11-12
US10286052B2 (en) 2019-05-14
JP2017524337A (ja) 2017-08-31
EA035456B1 (ru) 2020-06-18
EA201692103A1 (ru) 2017-04-28
MA49287A (fr) 2020-02-05
LT3140319T (lt) 2019-09-25
EP3140319B1 (fr) 2019-07-10
AU2015257652B2 (en) 2019-10-10
GB201408255D0 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
MA39907A (fr) Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2015193359A3 (fr) Nouvelle immunothérapie dirigée contre plusieurs tumeurs du sang, en particulier la leucémie lymphoïde chronique (llc)
SG10201900727QA (en) Personalized immunotherapy against several neuronal and brain tumors
MX2020011673A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
PH12016502008A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
MY198397A (en) Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
EA201990696A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга